Dr. Amany Keruakous discussed how bispecific antibodies for multiple myeloma work by simultaneously targeting cancer cells and T cells. Dr. Amany Keruakous sat down for an interview with CURE, in ...
Dr. Jacob A. Sands shares how antibody-drug conjugates, such as Datroway, work to selectively target and destroy tumor cells among those with lung cancer. Antibody-drug conjugates like Datroway ...
In blood cancers such as chronic lymphocytic leukemia, B cells of the immune system multiply uncontrollably. One form of therapy involves labeling the CD20 protein on the surface of the B cells with ...
Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these immune proteins can do more than that: They also activate other components of ...
Antibodies are immune proteins that our bodies produce to help fight off infection. Where they recognize and bind a pathogen — and how — can give important clues to the microbe’s vulnerabilities. Fred ...
Therapeutic antibodies have already revolutionized the management of many cancers, as well as autoimmune and inflammatory diseases. Their great strength? Their ability to pinpoint a biological target ...
W ith their ability to home in on precise targets while ignoring everything else, monoclonal antibodies are powerful ...
Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these immune proteins can do more than that: They also activate other components of ...
Monoclonal antibodies are a type of biologic medication that can treat moderate to severe inflammatory bowel disease (IBD) by targeting specific inflammatory processes in your body. Your doctor might ...
Antibodies are an important defense against SARS-CoV-2, but the virus continues to evolve ways to evade them. Now, researchers have mapped how antibodies target a key region of the virus's spike ...
Could monoclonal antibodies be the key to tackling the growing problem of antimicrobial resistance? A team led by researchers at the University of Cambridge has developed a monoclonal antibody drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results